Current Studies

On a website of the US National Institutes of Health many ongoing clinical studies are listed. Please note that this list is not complete.

Here are some of the many current clinical studies.

THC / Dronabinol / Marinol
Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia at Hadassah Medical Organization, Jerusalem, Israel.
For more studies please click here.

Nabilone / Cesamet
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis at University of Manitoba, Winnipeg, Canada.
For more studies please click here.

Nabiximols / Sativex
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer in the United States, the UK and Germany.
For more studies please click here.

Cannabidiol (CBD)
Cannabidiol for Inflammatory Bowel Disease at Meir Medical Center, Kefar Saba, Israel.
For more studies please click here.

Smoked / Inhaled Cannabis
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS at New York State Psychiatric Institute, USA.
Effects of Vaporized Marijuana on Neuropathic Pain at CTSC Clinical Research Center, Sacramento, United States.
For more studies please click here.

Contacto

Você esta aqui:Home > Lei e políticas > UK

UK

Laws
Court Rulings
Realities

Source: William Notcutt
Last update: 3 December 2008

Laws

Medicinal Cannabis

Plant Cannabis in any form (leaf, bud, resin etc.) is a Schedule 1 drug and not available for regular medicinal use.
Sativex, a medicinal extract, is licensed for:

             - Use in clinical trials
             - As an unlicensed drug for named patients. As such, it is managed and
               prescribed as a Schedule 4 drug

Nabilone is a synthetic cannabinoid, licenced for use in chemotherapy induced nausea and vomiting and is a Schedule 4 drug. It is widely used to treat pain and spasticity.
Dronabinol is not available in the UK
All cannabinoids are available for use in basic research projects.

Recreational Cannabis

Plant Cannabis in any form is a Class “C” illicit substance. This is the classification for legal purposes and reflects the potential harm of the drug. It also helps determine the punishment for possession or supply.
Currently the UK Government wants to reclassify Cannabis to “B” against the advice of the independent Advisory Council on the Misuse of Drugs.
Growing any Cannabis (for medicinal or recreational purposes) is illegal except under a Government licence. There are no exceptions.

Court Rulings

The defense of “Necessity” was used by patients growing or using plant cannabis as a medicine. This defense was taken to the House of Lords in 2004 and rejected.

Realities

Prosecutions for the possession of small amounts of cannabis for obvious medicinal use seem to be rare these days. This reflects a sympathetic and pragmatic approach by the police and judiciary.
Industrial growers and suppliers for the recreational market are the main target of the police.
Politicians and the media focus heavily on the potential psychiatric harm particularly in adolescents. However, the independent Advisory Council on the Misuse of Drugs has reviewed the evidence and do not find any strong links.
Sativex has been undergoing clinical trials for 8½ years now and still does not have a licence for clinical use. There is an increasing amount being used off-licence on a named-patient basis.

IACM Conference 2013

7th Conference on Cannabinoids in Medicine

The IACM Board of Directors would like to invite you to its 7th conference on Cannabinoids in September 2013 in Cologne.

European Workshop

6th European Workshop on Cannabinoids

18-20 April 2013
Trinity College Dublin, Ireland

Conference Website

Canadá

The University of British Columbia in partnership with the ICRS and the CCIC will organize “Cannabinoids in Clinical Practice” on 21 June 2013, a full day continuing medical education (CME) event.
More